Special Issue

Implementation of New Imaging Techniques, Biomarkers and New Treatments in Prostate Cancer

Message from the Guest Editors

We are living in an era of unprecedented development in prostate cancer, both in the diagnosis of the disease with the introduction of multiparametric magnetic resonance imaging and positron emission tomography (PET) with new radiotracers (PSMA, fluciclovine, etc.), as well as with the implementation of molecular biomarkers (serum and urinary markers, genomic classifiers, genes associated with alterations in DNA repair, mismatch repair, etc.) which have diagnostic and prognostic implications that can allow us to personalize the treatment for our patients. The number of therapeutic options for castration-resistant and metastatic prostate cancer has substantially increased over the last few vears. The traditional treatment for these patients (i.e., androgen deprivation therapy) is now considered suboptimal. Moreover, in patients with oligometastatic disease or low tumor burden, metastasis-directed therapy combined with systemic treatments is another area of growing interest. This Special Issue aims to explore the technological and therapeutic advances that already have a clinical use or that can transform the diagnostic and treatment paths of prostate cancer in the coming years.

Guest Editors

Dr. Felipe Couñago

- 1. Department of Medicine, Faculty of Medicine, Health and Sports, European University of Madrid, 28108 Madrid, Spain
- 2. Department of Radiation Oncology, GenesisCare, Hospital Universitario San Francisco de Asís y Hospital Universitario La Milagrosa, 28002 Madrid, Spain

Dr. Thomas Zilli

Dept Radiat Oncol, University of Geneva, Geneva, Switzerland

Dr. Fernando López Campos

Dept Radiat Oncol, Hospital Universitario Ramon y Cajal, Madrid, Spain

Deadline for manuscript submissions

closed (31 October 2022)



an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed



mdpi.com/si/101911

Biomedicines
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
biomedicines@mdpi.com

mdpi.com/journal/biomedicines





an Open Access Journal by MDPI

Impact Factor 3.9 CiteScore 6.8 Indexed in PubMed





About the Journal

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access iournal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to Biomedicines, be it original research, review articles, or developing Special Issues of current key topics.

Editor-in-Chief

Prof. Dr. Felipe Fregni

- Neuromodulation Center and Center for Clinical Research Learning, Spaulding Rehabilitation Hospital and Massachusetts General Hospital, Harvard Medical School, Boston, MA 02114, USA
- 2. Department of Epidemiology, Harvard T.H. Chan School of Public Health, Boston, MA 02115, USA

Author Benefits

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 17 days after submission; acceptance to publication is undertaken in 2.9 days (median values for papers published in this journal in the first half of 2025).